BioSpace News Archive

Atlas Antibodies AB has signed an agreement to acquire UK company HistoCyte Laboratories Ltd. HistoCyte Laboratories’ portfolio of innovative cell line materials provides control of immunohistochemical assays used in the diagnosis of cancers.

This project will highlight the sustainability credentials and advantages of BioHarvest’s BioFarming technology.

National Research Institute has participated in the enrollment of multiple COVID-19 vaccine trials, two of which have been led by NRI’s Chief Medical Officer, Mark Leibowitz, M.D. as Principal Investigator.

CAGE Bio Inc., an innovative biotechnology company focused on developing innovative therapies for infection, inflammation and immunology, announced the closing of a $7.2 million over-subscribed Series A financing.

Labcorp, a leading global life sciences company, announced that Amy Summy, executive vice president and chief marketing officer, was recognized on the 2021 Forbes CMO Next list for her leadership during the COVID-19 crisis, while also spearheading the rebranding strategy that highlighted the power of Labcorp’s combined diagnostic and drug development businesses.

Essent Biologics™, a nonprofit biotechnology company providing low passaged primary cells, origin tissue, scaffolds and data to advance regenerative medicine research, today announced the appointment of Derek Mathers as Head of Business Development.

Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today announced that it has closed its previously announced registered direct offering with certain healthcare i

ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, will report unaudited financial results for the year ended December 31, 2020 after the market closes on Monday, February 22, 2021.

Astrotech Corporation (NASDAQ: ASTC) reported its financial results for the second quarter of fiscal year 2021, which ended December 31, 2020. Since the beginning of the quarter, we successfully raised a total of $37.0 million in gross proceeds, strengthening our balance sheet for our future growth and expansion of our business.

First Investigational New Drug (IND) application cleared for NX-2127 in patients with relapsed and refractory B-cell malignancies Three additional wholly owned programs expected to enter clinical trials in 2021 Expanded Sanofi collaboration resulting in option exercise payment of $22 million Year-end cash and investments totaling $372 million